INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 41h ago
House PTR1h ago
SEC 13F1h ago
Robinhood Chain1h ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02SPSaba Capital Management, L.P.77B / 19S · 11 late96 trades$25.89M
  3. 03FWFogarty Patrick W0B / 90S90 trades$362K
  4. 04SJSheena Jonathan0B / 57S57 trades$3.61M
  5. 05ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  6. 06AJAllaire Jeremy0B / 50S50 trades$4.26M
  7. 07Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  8. 08SLSpeiser Michael L0B / 35S35 trades$14.00M
  9. 09RARothblatt Martine A0B / 33S33 trades$5.50M
  10. 10RJRubinstein Julie0B / 32S32 trades$5.48M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

71,797 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
KP
Kowalsky Matthew PaulChief Legal Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
1,318 sh
Feb 12, 2026Feb 13, 2026
Page 1314 of 1795
← PrevNext →
traded Feb 12, 2026
+1d
SEC Form 4

Evidence

9
SS
Sethi SubiChief Client Officer
CWANClearwater Analytics Holdings, Inc.
Grant or award
A—
216.0K sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

9
DA
Duran Richard ACHIEF INFORMATION OFFICER
EQTEQT Corp
Grant or award
A—
8,980 sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

8
CM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
ANIPANI PHARMACEUTICALS INC
Tax withholding
F$230K
3,011 sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

8
LR
Luly Jay R.Director, President and CEO
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$88K
6,155 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC Form 4

Evidence

5
LR
Luly Jay R.Director, President and CEO
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
4,800 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC Form 4

Evidence

5
DJ
Deshaies Robert JosephCOO, Benefits
WEXWEX Inc.
Option exercise
M—
1,032 sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

5
DM
DerGurahian Jeffrey MichaelChief Investment Officer
LDIloanDepot, Inc.
Derivative conversion
C—
1.60M sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

5
OS
Or Yat SunChief Scientific Officer
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$49K
3,413 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC Form 4

Evidence

5
DS
Das SouvikChief Technology Officer
CWANClearwater Analytics Holdings, Inc.
Grant or award
A—
142.5K sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

5
OS
Or Yat SunChief Scientific Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
5,225 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC Form 4

Evidence

5
LR
Luly Jay R.Director, President and CEO
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
15.2K sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC Form 4

Evidence

5
LB
Luu BrendanChief Business Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
1,575 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC Form 4

Evidence

5
DM
DerGurahian Jeffrey MichaelChief Investment Officer
LDIloanDepot, Inc.
Derivative conversion
C—
1.60M sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

5
OS
Or Yat SunChief Scientific Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
1,650 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC Form 4

Evidence

4
TP
Tuffin PaulaGeneral Counsel and CCO
BETRBetter Home & Finance Holding Co
Grant or award · 10b5-1 plan
A—
22.4K sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

2
HL
Hsieh Anthony LiDirector, Executive Chair, CEO & Pres., 10% Owner
LDIloanDepot, Inc.
Derivative conversion
C—
24.95M sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

2
HL
Hsieh Anthony LiDirector, Executive Chair, CEO & Pres., 10% Owner
LDIloanDepot, Inc.
Derivative conversion
C—
3.11M sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

2
HL
Hsieh Anthony LiDirector, Executive Chair, CEO & Pres., 10% Owner
LDIloanDepot, Inc.
Derivative conversion
C—
24.95M sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

2
HL
Hsieh Anthony LiDirector, Executive Chair, CEO & Pres., 10% Owner
LDIloanDepot, Inc.
Derivative conversion
C—
66.40M sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

2
HL
Hsieh Anthony LiDirector, Executive Chair, CEO & Pres., 10% Owner
LDIloanDepot, Inc.
Derivative conversion
C—
66.40M sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

2
HL
Hsieh Anthony LiDirector, Executive Chair, CEO & Pres., 10% Owner
LDIloanDepot, Inc.
Derivative conversion
C—
3.11M sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

2
HL
Hsieh Anthony LiDirector, Executive Chair, CEO & Pres., 10% Owner
LDIloanDepot, Inc.
Derivative conversion
C—
4.31M sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

2
HL
Hsieh Anthony LiDirector, Executive Chair, CEO & Pres., 10% Owner
LDIloanDepot, Inc.
Derivative conversion
C—
4.31M sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC Form 4

Evidence

0
PA
Perez Daniel AntonioDirector, CEO & Co-Founder, 10% Owner
HNGEHinge Health, Inc.
Derivative conversion · 10b5-1 plan
C—
166.7K sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC Form 4

Evidence

0
PA
Perez Daniel AntonioDirector, CEO & Co-Founder, 10% Owner
HNGEHinge Health, Inc.
Derivative conversion · 10b5-1 plan
C—
166.7K sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC Form 4

Evidence

55
MK
Mitchell KateDirector
RALRalliant Corp
Open-market purchase
BUY$100K
2,350 sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC Form 4

Evidence

51
GL
Goldstein Robert L.Chief Operating Officer
BLKBlackRock, Inc.
Open-market sale
SELL$19.63M
18.0K sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC Form 4

Evidence

47
GJ
Garnett Timothy JohnDirector
MPLTMapLight Therapeutics, Inc.
Open-market purchase
BUY$253K
14.1K sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC Form 4

Evidence

44
GL
Goldstein Robert L.Chief Operating Officer
BLKBlackRock, Inc.
Open-market sale
SELL$6.10M
5,608 sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC Form 4

Evidence

44
GL
Goldstein Robert L.Chief Operating Officer
BLKBlackRock, Inc.
Open-market sale
SELL$6.43M
5,924 sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC Form 4

Evidence

44
GL
Goldstein Robert L.Chief Operating Officer
BLKBlackRock, Inc.
Open-market sale
SELL$9.48M
8,708 sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC Form 4

Evidence

44
GL
Goldstein Robert L.Chief Operating Officer
BLKBlackRock, Inc.
Open-market sale
SELL$9.77M
8,992 sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC Form 4

Evidence

40
GL
Goldstein Robert L.Chief Operating Officer
BLKBlackRock, Inc.
Open-market sale
SELL$1.32M
1,215 sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC Form 4

Evidence

40
GL
Goldstein Robert L.Chief Operating Officer
BLKBlackRock, Inc.
Open-market sale
SELL$4.16M
3,839 sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC Form 4

Evidence

40
GL
Goldstein Robert L.Chief Operating Officer
BLKBlackRock, Inc.
Open-market sale
SELL$1.90M
1,740 sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC Form 4

Evidence

39
CM
Cohn MatthewDirector
TBBKBancorp, Inc.
Open-market purchase
BUY$22K
355 sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC Form 4

Evidence

39
CM
Cohn MatthewDirector
TBBKBancorp, Inc.
Open-market purchase
BUY$20K
325 sh
Feb 10, 2026Feb 12, 2026
traded Feb 10, 2026
+2dSEC Form 4

Evidence

38
SJ
Steinmetz JohnExec Mng Dir of Strategic Init
NBHCNational Bank Holdings Corp
Open-market purchase
BUY$1.00M
24.2K sh
Feb 11, 2026Feb 12, 2026
traded Feb 11, 2026
+1dSEC Form 4

Evidence

36
CM
Cohn MatthewDirector
TBBKBancorp, Inc.
Open-market purchase
BUY$9,688
170 sh
Feb 11, 2026Feb 12, 2026
traded Feb 11, 2026
+1dSEC Form 4

Evidence